No Data
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $25
Express News | Astria Therapeutics Shares Are Trading Higher After the Company Reported Q2 Financial Results. Also, Oppenheimer Maintained an Outperform Rating on the Stock and Raised Its Price Target From $25 to $26
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
Express News | Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $26 From $25